cerebral infarction except cardioembolic cerebral embolism
Conditions
Interventions
2 years after permission cilostasol group:200mg a day oral intake
2 years after permission aspirin group:100mg a dat oral intake
Sponsors
Neurosurgery, Tokushima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. age between 20 and 89 years old 2. patients diagnosed as cerebral infarction by CT or MRI 3. newly diagnosed as cerebral infarction except cardioembolic stroke 4.National institute of Health stroke scale at initial assessment is below 20 5. possible intake of antiplatelet within 7 days after stroke onset 6.modified Rankin scale before stroke onset is below 3 7. patients can be monitored over 3 months 8.patients obtained informed consent
Exclusion criteria
Exclusion criteria: 1. hemorrhage of hemorrhagic tendenncy 2. indicatied for fibrinokytis therapy using t-PA 3. unable to take antiplatelets 4. allergy for antiplatelets using in this study 5. conttraindicated for drugs using in this study 6. bed ridden state or no expectancy to improve activity of daily life 7. transient ischemic attack 8. other taking drugs are contraindicated to take with antiplatelets using in this study 9. patients enrolled in other clinical trial 10. patients who are assessed inappropriate to enroll in this study by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| activity of daily life improvement effect of the depression | — |
Secondary
| Measure | Time frame |
|---|---|
| recurrence of the ischemic stroke cardiovascular adverse event hemorrhagic complication | — |
Countries
Japan
Outcome results
None listed